PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-304.05%
Negative net income growth while AXSM stands at 19.26%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
194.69%
Working capital change of 194.69% while AXSM is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might affect near-term cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
176.34%
A yoy AP increase while AXSM is negative at -56.31%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-34.25%
Negative yoy usage while AXSM is 100.00%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
198.30%
Some yoy increase while AXSM is negative at -19.79%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
56.08%
Operating cash flow growth above 1.5x AXSM's 25.25%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
100.00%
CapEx growth of 100.00% while AXSM is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth well above AXSM's 96.15%. Michael Burry would suspect heavier intangible or side spending overshadowing competitor’s approach, risking short-term FCF.
100.00%
Investing outflow well above AXSM's 96.15%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
42.27%
We repay more while AXSM is negative at -29.18%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.